A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of Avalglucosidase Alfa (neoGAA, GZ402666) and Alglucosidase Alfa in Treatment naïve Patients With Late-onset Pompe Disease

Primary Objective:

To determine the effect of avalglucosidase alfa treatment on respiratory muscle strength
measured by percent (%) predicted forced vital capacity (FVC) in the upright position, as
compared to alglucosidase alfa.

Secondary Objective:

To determine the safety and effect of avalglucosidase alfa treatment on functional endurance
(6-minute walk test, inspiratory muscle strength (maximum inspiratory pressure), expiratory
muscle strength (maximum expiratory pressure), lower extremity muscle strength (hand-held
dynamometry), motor function (Quick Motor Function Test), and health-related quality of life
(Short Form-12).